

# Radioimmunotherapy

[View the current Radioimmunotherapy InDepth page on BioPortfolio.com](#) ([PDF](#))

(<http://www.bioportfolio.com/indepth/Radioimmunotherapy.html>) - Regularly Updated.

Radio immunotherapy utilizes an antibody labeled with a radionuclide to deliver cytotoxic radiation to a target cell. In cancer therapy, an antibody with specificity for a tumor-associated antigen is used to deliver a lethal dose of radiation to the tumor cells. The ability for the antibody to specifically bind to a tumor-associated antigen increases the dose delivered to the tumor cells while decreasing the dose to normal tissues. By its nature, RIT requires a tumor cell to express an antigen that is unique to the neoplasm or is not accessible in normal cells. ([From the Wikipedia article Radioimmunotherapy](#).)

## Recent Publications on Radioimmunotherapy:



- [Preparation and evaluation of \(186/188\)Re-labeled antibody \(A7\) for radioimmunotherapy with rhenium\(I\) tricarbonyl core as a chelate site.](#)  
*OBJECTIVE: Rhenium is one of the most valuable elements for internal...* 19th November, 2009  
Graduate School of Natural Science and Technology, Kanazawa University,- Ann Nucl Med. 2009 Nov 17. ([DOI Direct Link](#))
- [Radioimmunotherapy of Breast Cancer Metastases with {alpha}-Particle Emitter 225Ac: Comparing Efficacy with 213Bi and 90Y.](#)  
*alpha-Particles are suitable to treat cancer micrometastases because of...* 19th November, 2009  
Division of Nuclear Medicine, Russell H. Morgan Department of Radiology- Cancer Res. 2009 Nov 17. ([DOI Direct Link](#))
- [Noninternalizing Monoclonal Antibodies Are Suitable Candidates for 125I Radioimmunotherapy of Small-Volume Peritoneal Carcinomatosis.](#)  
*We have previously shown that, in vitro, monoclonal antibodies (mAbs)...* 17th November, 2009  
Institut de Recherche en Cancerologie de Montpellier, Montpellier, France;- J Nucl Med. 2009 Nov 12. ([DOI Direct Link](#))
- [\[Guideline for radioimmunotherapy of CD20+ follicular B-cell non-Hodgkin s lymphoma.\]](#)  
*This guideline is a prerequisite for the quality management in the...* 11th November, 2009  
Prof. Dr. Manfred Fischer, Im Bodden 60, 34125 Kassel, Germany.- Nuklearmedizin. 2009 Nov 9;48(6). ([DOI Direct Link](#))
- [Anti-Infective Strategies of the Future: Is there Room for Species-Specific Antibacterial Agents?](#)  
*Broad-spectrum antibiotics, directed against conserved bacterial targets,...* 11th November, 2009  
Microbiology Consultant, D-79576 Weil am Rhein, Germany.- Curr Pharm Des. 2009 Nov 10.
- [Compartmental intrathecal radioimmunotherapy: results for treatment for metastatic CNS neuroblastoma.](#)  
*Innovation in the management of brain metastases is needed. We evaluated...* 6th November, 2009  
Department of Pediatrics, Memorial Sloan-Kettering Cancer Center, 1275- J Neurooncol. 2009 Nov 5. ([DOI Direct Link](#))

- [Good things come in small packages: low-dose radiation as palliation for indolent non-Hodgkin lymphomas.](#)  
*Numerous management options are available to patients with advanced-stage...*4th November, 2009  
Harvard Radiation Oncology Program, Brigham and Women's- Leuk Lymphoma. 2009 Nov;50(11):1765-72.
- [Localization of radiolabeled anti-CEA antibody in subcutaneous and intrahepatic colorectal xenografts: influence of tumor size and location within host organ on antibody uptake.](#)  
*INTRODUCTION: Radioimmunotherapy (RIT) has been shown to be more effective...*31st October, 2009  
Cancer Research UK Targeting and Imaging Group, Research Department of- Nucl Med Biol. 2009 Nov;36(8):883-94. Epub 2009 Oct 3. ([DOI Direct Link](#))
- [Pretargeted radioimmunotherapy in the treatment of metastatic medullary thyroid cancer.](#)  
*INTRODUCTION: Radioimmunotherapy (RIT) has been shown to be more effective...*29th October, 2009  
Nuclear Medicine Department, University Hospital, Nantes, France.- *Curr Oncol.* 2009 Sep;16(5):3-8.
- [Repeated Intraperitoneal alpha-Radioimmunotherapy of Ovarian Cancer in Mice.](#)  
*The aim of this study was to investigate the therapeutic efficacy of...*28th October, 2009  
Institute of Clinical Sciences, The Sahlgrenska Academy, University of- *J Oncol.* 2010;2010:394913. Epub 2009 Oct 25. ([DOI Direct Link](#))
- [Late FDG PET normalization after radioimmunotherapy in a patient with non-Hodgkin lymphoma.](#)  
*Fluoro-deoxy-glucose positron emission tomography (FDG PET) has largely...*24th October, 2009  
Unita Operativa di Medicina Nucleare, Policlinico S. Orsola-Malpighi,- *Clin Nucl Med.* 2009 Nov;34(11):777-8. ([DOI Direct Link](#))
- [Radioimmunotherapy for stem cell transplantation in non-Hodgkin's lymphoma: in pursuit of a complete response.](#)  
*High-dose chemotherapy (HDC) conditioning given in association with...*21st October, 2009  
Hopital Saint-Louis, Hemato-oncologie, 1 Avenue Claude Vellefaux, Paris- *Oncologist.* 2009;14 Suppl 2:41-51. ([DOI Direct Link](#))
- [Rationale for consolidation to improve progression-free survival in patients with non-Hodgkin's lymphoma: a review of the evidence.](#)  
*Non-Hodgkin's lymphoma (NHL) comprises both indolent forms, including...*21st October, 2009  
Department of Hematology, Hopital Claude Huriez, F-59037 Lille, France.- *Oncologist.* 2009;14 Suppl 2:17-29. ([DOI Direct Link](#))
- [Harnessing the energy: development of radioimmunotherapy for patients with non-Hodgkin's lymphoma.](#)  
*Radioimmunotherapy (RIT) combines the use of targeted monoclonal...*21st October, 2009  
Section of Hematology, Rush University Medical Center/Rush University,- *Oncologist.* 2009;14 Suppl 2:4-16. ([DOI Direct Link](#))

## BioNews Results for Radioimmunotherapy

- [Spectrum Pharma: Zevalin Has Blockbuster Potential](#)  
*Seeking Alpha: Oct 25 2009 1:51PM Matching: radioimmunotherapy*
- [Manchester scientists take on cancer with pioneering radiotherapy treatment](#)  
*Cancer Research UK: Oct 14 2009 2:27AM Matching: radioimmunotherapy*



## Radioimmunotherapy Patents:

- 7553814- [238P1B2 protein](#)
- 7582281- [Ethylenedicysteine \(EC\)-drug conjugates compositions and methods for tissue specific disease imaging](#)
- 7585505- [Nucleic acid and corresponding protein entitled 161P2F10B useful in treatment and detection of cancer](#)
- 7585893- [Anti-cancer composition comprising DMXAA or related compound](#)
- 7589180- [Specific binding proteins and uses thereof](#)
- 7591994- [Camptothecin-binding moiety conjugates](#)
- 7592149- [Nucleic acid and corresponding protein entitled 184P1E2 useful in treatment and detection of cancer](#)
- 7592426- [Anti-mesothelin antibodies](#)
- 7595379- [Antibodies and related molecules that bind to PSCA proteins](#)
- 7597862- [Process for radioisotope recovery and system for implementing same](#)
- 7598030- [Antibodies against cancer produced using masked cancer cells as immunogen](#)
- 7579187- [Anti-A33 antibody](#)
- 7576066- [Nucleic acid compositions for stimulating immune responses](#)
- 7574251- [Method and system for adapting a radiation therapy treatment plan based on a biological model](#)
- 7553953- [Chimeric, human and humanized anti-CSAp monoclonal antibodies](#)
- 7557251- [Production of gossypol co-crystals](#)
- 7557353- [Single-use external dosimeters for use in radiation therapies](#)
- 7560095- [Cancer specific monoclonal antibodies](#)
- 7560110- [Production and use of novel peptide-based agents with bispecific antibodies](#)
- 7563439- [Production and use of novel peptide-based agents for use with bi-specific antibodies](#)
- 7563444- [Nucleic acid and corresponding protein entitled 213P1F11 useful in treatment and detection of cancer](#)
- 7563882- [Polynucleotides encoding antibodies that bind to the C35 polypeptide](#)
- 7569341- [Nucleic acid directed immobilization arrays and methods of assembly](#)
- 7569553- [Nucleic acid compositions for stimulating immune responses](#)
- 7598042- [Early prostate cancer antigens \(EPCA\), polynucleotide sequences encoding them, and their use](#)
- 7598058- [Nucleic acids encoding IL13 mutants](#)
- 7612178- [Anti-IGF-1R antibodies and uses thereof](#)
- 7612179- [antibodies binding to a C-terminal fragment of apolipoprotein E](#)
- 7612180- [Humanized L243 antibodies](#)
- 7612181- [Dual variable domain immunoglobulin and uses thereof](#)
- 7615208- [Metal ion-labeled bis-aminoethanethiol-targeting ligand conjugates, compositions, and methods for tissue-specific disease imaging](#)
- 7615213- [Antibodies against human interleukin-13 and pharmaceutical compositions thereof](#)
- 7615372- [Antibodies with immune effector activity and that internalize in endosomal-positive cells](#)
- 7615379- [Nucleic acid and corresponding protein entitled 193P1E1B useful in treatment and detection of cancer](#)
- 7618613- [Method for radiolabeling antibodies with yttrium-90](#)
- 7618625- [Compositions comprising large and small binding fragments of antibodies against the same](#)

toxin

- 7612172- [Nucleic acids and corresponding proteins entitled 282P1G3 useful in treatment and detection of cancer](#)
- 7612032- [Method for treating oncological diseases](#)
- 7611692- [Gastrin releasing peptide compounds](#)
- 7598353- [Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof](#)
- 7601335- [Pretreatment of a biological sample from an autoimmune disease subject](#)
- 7601341- [Vascular endothelial growth factor fusion constructs used to inhibit osteoclastogenesis](#)
- 7601511- [Biotin-facilitated transport in gram negative bacteria](#)
- 7601825- [Nucleic acid and corresponding protein entitled 121P1F1 useful in treatment and detection of cancer](#)
- 7605138- [Nucleic acid compositions for stimulating immune responses](#)
- 7605234- [Specific binding proteins including antibodies which bind to the necrotic centre of tumours, and uses thereof](#)
- 7605239- [Skeletal-targeted radiation to treat bone-associated pathologies](#)
- 7608241- [Radiolabeling method](#)
- 7608618- [Urea or thiourea substituted 1,4-pyrazine compounds useful as anti-cancer agents and for inhibiting Chk1](#)
- 7618627- [Method of increasing radiation sensitivity by inhibition of beta one integrin](#)

\*\*\*

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Stafford House, 10 Prince of Wales Road, Dorchester, Dorset, DT1 1PW, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2009 - BioPortfolio Limited.

